Transgene Announces Temporary Trading Suspension
Transgene, a pioneering biotechnology company focused on developing immunotherapy products for cancer treatment, has recently announced a significant step regarding its shares on Euronext Paris. This move, effective before the markets open on a Wednesday, marks a strategic pause in trading as the company prepares to share pivotal results concerning its capital increase.
Details of the Trading Suspension
Starting from a specified Wednesday, the trading of Transgene shares (Euronext Paris: TNG) will be temporarily halted. This suspension has been initiated as part of the company’s process to disclose details about its anticipated capital increase. According to updates, the trading is expected to resume promptly on the following Thursday, ensuring minimal disruption while fostering a transparent environment for investors and stakeholders alike.
Reasons for the Suspension
The trading suspension stems from Transgene’s ongoing efforts to raise capital, essential for advancing its innovative research in cancer therapies. This strategic decision enables the company to enhance its funding capabilities and implement various development projects within its promising portfolio. Maintaining a robust financial foundation is crucial as Transgene seeks to pave the way for groundbreaking treatments in oncological care.
About Transgene and Its Innovations
Transgene was established to address the pressing need for effective cancer treatments. Through its diligent efforts, the company has developed several leading-edge immunotherapy products. Notably, the myvac® platform is at the forefront of its offerings. Among these, TG4050, a personalized immunotherapy that tailors treatment based on individual tumor characteristics, shows promising results in clinical trials for head and neck cancers.
Portfolio of Cancer Therapies
The company also works on additional candidates like BT-001, which utilizes an oncolytic virus to confront tumors. Both the myvac® and the innovative invir.IO® platform demonstrate Transgene's commitment to harnessing advanced scientific methodologies. Invir.IO®, with its unique design capabilities for oncolytic viruses, signifies a new era of treatment strategies tailored to the unique biology of individual cancers.
Looking Ahead: Investor Relations and Future Developments
Transgene's management is keenly focused on maintaining open lines of communication with its investors and analysts. The Chief Financial Officer and investor relations team are available to address any queries regarding the company's strategic decisions and future prospects. Their commitment to transparency underscores a dedication to building trust with stakeholders as the company progresses through this capital-raising phase.
Contact Information
For further inquiries, investors can reach out to Caroline Tosch, Corporate and Scientific Communications Manager, or Lucie Larguier, the Chief Financial Officer. Contact numbers are provided for direct communication, ensuring stakeholders remain informed during this pivotal time.
Frequently Asked Questions
What prompted Transgene to suspend trading?
Transgene initiated the trading suspension on Euronext Paris to prepare for and announce results related to its capital increase.
When will trading resume?
Trading is expected to resume on the following Thursday after the suspension is implemented.
What is the primary focus of Transgene's development?
Transgene specializes in immunotherapy products aimed at cancer treatment, with innovative platforms for personalized medicine.
How does Transgene ensure transparency with investors?
Transgene maintains open communication through direct contact with its media and investor relations teams, providing updates and addressing any concerns.
What innovative therapies are currently in Transgene's portfolio?
Transgene's portfolio includes therapies like TG4050 and BT-001, both designed to leverage advanced technologies for effective cancer treatment.
